PMID: 9434921Jan 22, 1998Paper

The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease

Intensive Care Medicine
R SchererJ Peters

Abstract

Since antithrombin III (AT III) substitution to normal activities could not be shown to have major beneficial effects in patients with end-stage chronic liver disease in a variety of clinical settings, we tested the hypothesis that substitution to supranormal activities decreases systemic procoagulant turnover better in this patient group. Controlled prospective clinical study. Operating rooms at a University Hospital. Twenty-four patients with histologically verified liver cirrhosis consecutively scheduled for liver transplantation. Nineteen patients were given an antithrombin III concentrate to achieve either 100% (n = 10) or 175% (n = 9) AT III activity. Control patients (n = 5) received saline 0.9% instead. Molecular markers of coagulation activation, platelet count and aggregability, and global coagulation variables were measured prior to AT III infusion and 60 min thereafter. In both AT III-treated groups thrombin-antithrombin III-complex increased significantly (p < 0.005), whereas prothrombin fragment F1 + 2, soluble fibrin and D-dimer concentrations, as well as other variables, did not show major changes. Despite thrombin inhibition by AT III in patients with end-stage chronic liver disease, systemic procoagulant turno...Continue Reading

References

Jun 1, 1978·European Journal of Clinical Investigation·D CollenM Verstraete
Jun 1, 1978·Thrombosis Research·L H KahléJ W ten Cate
Jan 1, 1977·Seminars in Thrombosis and Hemostasis·K LechnerE Thaler
Jul 1, 1975·Annals of Internal Medicine·M ColemanM Pasmantier
May 1, 1992·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·F J Walker, P J Fay
Oct 1, 1987·Seminars in Thrombosis and Hemostasis·J A Marcum, R D Rosenberg
May 15, 1986·The New England Journal of Medicine·L H Clouse, P C Comp
Jan 1, 1974·Annual Review of Medicine·M VerstraeteD Collen
Aug 1, 1971·The Journal of Clinical Investigation·G N TytgatM Verstraete
Apr 10, 1984·Biochemistry·J A Marcum, R D Rosenberg
May 1, 1984·Journal of Clinical Pathology·E KnotG N Tytgat
Sep 1, 1982·British Journal of Haematology·H G Schipper, J W ten Cate
Mar 1, 1993·Journal of Hepatology·P G LangleyR Williams

❮ Previous
Next ❯

Citations

Jul 5, 2005·Critical Care Clinics·Jody L Kujovich
May 15, 2001·European Journal of Anaesthesiology·Y OzierP De Moerloose
Jan 5, 2001·Baillière's Best Practice & Research. Clinical Gastroenterology·P A McCormick, K M Murphy
Oct 16, 1999·The American Journal of Gastroenterology·J H Joist
Feb 1, 2005·World Journal of Gastroenterology : WJG·Sasa-Marcel MaksanJan Schmidt
Feb 10, 2016·The Cochrane Database of Systematic Reviews·Mikkel AllingstrupArash Afshari
Jul 13, 2006·International Anesthesiology Clinics·Theo H N Groenland, Robert J Porte
Oct 3, 2006·Current Opinion in Anaesthesiology·R U Scherer, S Pulletz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.